- Type / Class
- Equity / COM
- Shares outstanding
- 258,506,508
- Total 13F shares
- 136,753,565
- Share change
- +11,418,338
- Total reported value
- $303,582,298
- Put/Call ratio
- 53%
- Price per share
- $2.22
- Number of holders
- 173
- Value change
- +$17,706,459
- Number of buys
- 103
- Number of sells
- 54
Quarterly Holders Quick Answers
What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29664W105:
Top shareholders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
5.3%
|
13,708,731
|
$36,739,399 | — | 31 Mar 2024 | |
| Bellevue Group AG |
13F
|
Company |
3.8%
|
9,944,064
|
$26,650,092 | — | 31 Mar 2024 | |
| WASATCH ADVISORS LP |
13F
|
Company |
3.5%
|
9,129,647
|
$24,467,454 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
8,826,546
|
$23,655,143 | — | 31 Mar 2024 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
3.1%
|
8,000,000
|
$21,440,000 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
3.1%
|
7,922,229
|
$21,231,574 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
2.2%
|
5,681,744
|
$15,227,074 | — | 31 Mar 2024 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
5,143,486
|
$13,784,542 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.8%
|
4,545,260
|
$12,181,297 | — | 31 Mar 2024 | |
| Two Seas Capital LP |
13F
|
Company |
1.6%
|
4,165,657
|
$11,163,961 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
1.5%
|
3,975,560
|
$10,654,501 | — | 31 Mar 2024 | |
| Meditor Group Ltd |
13F
|
Company |
1.5%
|
3,791,300
|
$10,160,684 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
1.4%
|
3,569,700
|
$9,566,796 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
3,364,266
|
$9,016,233 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.3%
|
3,362,210
|
$9,010,723 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.1%
|
2,838,820
|
$7,608,039 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.86%
|
2,215,961
|
$5,938,775 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.82%
|
2,116,500
|
$5,672,000 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.81%
|
2,085,101
|
$5,588,070 | — | 31 Mar 2024 | |
| BIOTECH TARGET N V |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,477,964
|
$5,575,065 | — | 24 May 2021 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.79%
|
2,045,769
|
$5,482,661 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.68%
|
1,753,193
|
$4,699,593 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.64%
|
1,642,360
|
$4,401,524 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.62%
|
1,607,312
|
$4,307,596 | — | 31 Mar 2024 | |
| PLATINUM INVESTMENT MANAGEMENT LTD |
13F
|
Company |
0.62%
|
1,597,542
|
$4,281,413 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.44%
|
1,142,897
|
$3,062,964 | — | 31 Mar 2024 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.38%
|
983,343
|
$2,635,359 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.37%
|
947,506
|
$2,539,315 | — | 31 Mar 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.27%
|
704,097
|
$1,886,980 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.21%
|
551,249
|
$1,477,347 | — | 31 Mar 2024 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.17%
|
449,129
|
$1,204,000 | — | 31 Mar 2024 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.17%
|
442,030
|
$1,184,000 | — | 31 Mar 2024 | |
| Man Group plc |
13F
|
Company |
0.17%
|
440,770
|
$1,181,264 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.14%
|
360,827
|
$967,016 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.14%
|
356,748
|
$956,085 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.12%
|
308,677
|
$827,254 | — | 31 Mar 2024 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.12%
|
300,300
|
$804,804 | — | 31 Mar 2024 | |
| PINNACLE ASSOCIATES LTD |
13F
|
Company |
0.11%
|
285,204
|
$764,347 | — | 31 Mar 2024 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.11%
|
273,292
|
$732,423 | — | 31 Mar 2024 | |
| Parallel Advisors, LLC |
13F
|
Company |
0.09%
|
239,000
|
$640,520 | — | 31 Mar 2024 | |
| Walleye Capital LLC |
13F
|
Company |
0.09%
|
227,630
|
$610,048 | — | 31 Mar 2024 | |
| DAVIDSON KEMPNER CAPITAL MANAGEMENT LP |
13F
|
Company |
0.09%
|
222,482
|
$594,027 | — | 31 Mar 2024 | |
| NJ State Employees Deferred Compensation Plan |
13F
|
Company |
0.08%
|
195,125
|
$522,935 | — | 31 Mar 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.07%
|
187,166
|
$496,000 | — | 31 Mar 2024 | |
| Marex Group plc |
13F
|
Company |
0.07%
|
175,000
|
$469,000 | — | 31 Mar 2024 | |
| Marathon Trading Investment Management LLC |
13F
|
Company |
0.07%
|
170,500
|
$456,940 | — | 31 Mar 2024 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.06%
|
166,457
|
$446,105 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.06%
|
159,038
|
$426,222 | — | 31 Mar 2024 | |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) |
13F
|
Company |
0.06%
|
142,418
|
$381,680 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0.05%
|
120,759
|
$323,634 | — | 31 Mar 2024 |
Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) as of Q2 2024
As of 30 Jun 2024,
Esperion Therapeutics, Inc. - COM (ESPR) was held by
173 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
136,753,565 shares.
The largest 10 holders included
WASATCH ADVISORS LP, BlackRock Inc., VANGUARD GROUP INC, Bellevue Group AG, MILLENNIUM MANAGEMENT LLC, GREAT POINT PARTNERS LLC, Two Seas Capital LP, Woodline Partners LP, MARSHALL WACE, LLP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
174
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
147
Q2 2024 holders
173
Holder diff
26
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.